The anti‐AML activity of BTZ was also investigated in a xenograft model of leukaemia, and the ability of BTZ to reduce the development of KG‐1a cell xenografts in the bone marrow of NSG mice was evaluated (Figure 8). The gene discussed is CASC3; the disease is leukemia.